Q32 Bio Inc. (QTTB): Nasdaq/NYSE listing notice — Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency

Q32 Bio Inc.

Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.
Also failed market value ($35M) and net income ($0.5M) alternatives.
Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 days.
Bempikibart-related liability of $55M from Amgen re-acquisition contributes to deficit.
No immediate effect on listing; stock continues trading under QTTB.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Q32 Bio Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1), 5550(b)(2), 5550(b)(3)

Exact text from the filing

May 19, 2025, Q32 Bio Inc. (“Q32 Bio” or the “Company”) received written notice (the “Notice”) from the listing qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 which reported the Company’s stockholders’ equity (deficit) of approximately ($4.0 million), the Company is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market per Listing Rule 5550(b)(1). Additionally, t

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-125435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.